Rifaximin
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 1767 publications
A multi-compound dietary supplement to improve the well-being of symptomatic uncomplicated diverticular disease.
Journal: Minerva gastroenterology
Published: March 30, 2026
The role of systemic inflammation in hepatic encephalopathy: advances in inflammatory mechanisms, prevention and treatment research.
Journal: Annals of medicine
Published: March 29, 2026
Optimal use of rifaximin in diverticular disease of the colon: use less for use better.
Journal: Gut
Published: March 07, 2026
Hepatic encephalopathy in liver cirrhosis
Journal: Deutsche medizinische Wochenschrift (1946)
Published: February 09, 2026
Enteropathogenic Escherichia coli and Bacterial Overgrowth Co-infection Exacerbating Immune Checkpoint Inhibitor-Induced Colitis.
Journal: Cureus
Published: February 07, 2026
Azathioprine combined with either rifaximin (A microecological inhibitor) or infliximab for inflammatory bowel disease: Differential impacts on intestinal barrier function, inflammatory response and stress injury.
Journal: Pakistan journal of pharmaceutical sciences
Published: February 01, 2026
Biomarkers in Irritable Bowel Syndrome: Rationale and Practical Use.
Journal: Gastroenterology clinics of North America
Published: January 25, 2026
Letter: Rifaximin Versus Low FODMAP Diet in IBS: What the Primary Endpoint Does Not Tell Us. Authors' Reply.
Journal: Alimentary pharmacology & therapeutics
Published: January 19, 2026
Branched-chain amino acids for people with cirrhosis and hepatic encephalopathy.
Journal: The Cochrane database of systematic reviews
Published: January 16, 2026
Comparison of Surgery and Medicine on the Impact of Diverticulitis (COSMID) trial: a protocol for a pragmatic randomised study of diverticulitis treatment in the USA.
Journal: BMJ open
Published: January 08, 2026
Last Updated: 04/28/2026